Literature DB >> 10147026

Indices of therapeutic outcome in pharmacoeconomic evaluation of drug therapy.

S F Hurley1.   

Abstract

Mesh:

Year:  1992        PMID: 10147026     DOI: 10.2165/00019053-199201030-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  29 in total

1.  Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands.

Authors:  L L Martens; F F Rutten; D W Erkelens; C A Ascoop
Journal:  Am J Cardiol       Date:  1990-03-20       Impact factor: 2.778

2.  Challenges for cost-effectiveness research.

Authors:  M C Weinstein
Journal:  Med Decis Making       Date:  1986 Oct-Dec       Impact factor: 2.583

3.  A cost-effectiveness comparison of the use of antimicrobial agents for treatment or prophylaxis of travelers' diarrhea.

Authors:  R R Reves; P C Johnson; C D Ericsson; H L DuPont
Journal:  Arch Intern Med       Date:  1988-11

4.  Cost-effectiveness of prenatal screening and immunization for hepatitis B virus.

Authors:  J A Arevalo; A E Washington
Journal:  JAMA       Date:  1988-01-15       Impact factor: 56.272

5.  Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Multicenter AIDS Cohort Study.

Authors:  N M Graham; S L Zeger; L P Park; J P Phair; R Detels; S H Vermund; M Ho; A J Saah
Journal:  Lancet       Date:  1991-08-03       Impact factor: 79.321

6.  Strategy of prevention: lessons from cardiovascular disease.

Authors:  G Rose
Journal:  Br Med J (Clin Res Ed)       Date:  1981-06-06

7.  Prevention and control of type A influenza infections in nursing homes. Benefits and costs of four approaches using vaccination and amantadine.

Authors:  P A Patriarca; N H Arden; J P Koplan; R A Goodman
Journal:  Ann Intern Med       Date:  1987-11       Impact factor: 25.391

8.  Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model.

Authors:  B E Hillner; T J Smith
Journal:  N Engl J Med       Date:  1991-01-17       Impact factor: 91.245

9.  Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.

Authors:  L Goldman; M C Weinstein; P A Goldman; L W Williams
Journal:  JAMA       Date:  1991-03-06       Impact factor: 56.272

Review 10.  Cost-effectiveness of primary tetanus vaccination among elderly Canadians.

Authors:  B G Hutchison; G L Stoddart
Journal:  CMAJ       Date:  1988-12-15       Impact factor: 8.262

View more
  3 in total

Review 1.  Drug utilisation review and pharmacoeconomics: interaction after parallel development?

Authors:  S Garattini; G Tognoni
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

2.  Necessity of using intermediate outcome to proxy long term effects. The example of thrombolytics.

Authors:  J S Schwartz
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

3.  Pharmacoeconomics: a challenge for clinical pharmacologists.

Authors:  T Walley; P Davey
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.